Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

HLA Class I Allele-Deficient Clones Regenerate in Immune Aplastic Anemia without Anti-Thymocyte Globulin

Yoshitaka Zaimoku, Kazuyoshi Hosomichi, Noriaki Tsuji, Mikoto Tanabe, Noriharu Nakagawa, Takeshi Yoroidaka, Hiroki Mizumaki, Tatsuya Imi, Hiroyuki Maruyama, Kohei Hosokawa, Hiroyuki Takamatsu, Hirohito Yamazaki, Kazuya Sakai, Ishikazu Mizuno, Toshihiro Miyamoto, Shinji Nakao

Blood (2024) 144 (Supplement 1): 1307.

https://doi.org/10.1182/blood-2024-208660

Published: 2024

Journal Articles

Immediate Therapeutic Intervention for Acute Mortality in Immune-Mediated Thrombotic Thrombocytopenic Purpura with Positive Chest Findings at Initial Presentation

Blood (2024) 144 (Supplement 1): 2621.

https://doi.org/10.1182/blood-2024-202956

Published: 2024

Journal Articles

Persistent ADAMTS13 Inhibitor May Lead to Delayed ADAMTS13 Recovery in Japanese Patients with Caplacizumab-Treated Immune-Mediated Thrombotic Thrombocytopenic Purpura

Kenki Saito, Kazuya Sakai, Masayuki Kubo, Hidekazu Azumi, Atsushi Hamamura, Shinichi Ochi, Shinya Kobayashi, Hideo Yagi, Masanori Matsumoto

Blood (2023) 142 (Supplement 1): 695.

https://doi.org/10.1182/blood-2023-179143

Published: 2023

Journal Articles

Value of Prophylactic Plasma Treatment and Incidence of Acute Episodes in Patients Enrolled in the International Hereditary Thrombotic Thrombocytopenic Purpura Registry

Blood (2023) 142 (Supplement 1): 691.

https://doi.org/10.1182/blood-2023-184580

Published: 2023

Journal Articles

Insight into the Natural History of Hereditary Thrombotic Thrombocytopenic Purpura: Short- and Long-Term Outcomes in a Longitudinally Followed Large Patient Cohort of the International Hereditary TTP Registry

Blood (2023) 142 (Supplement 1): 4003.

https://doi.org/10.1182/blood-2023-185053

Published: 2023

Journal Articles

Caplacizumab Frontline Added to Therapeutic Plasma Exchange and Immunosuppression Prevents Unfavorable Outcomes in Immune-Mediated TTP: An International Real-World Study of the TTP-IWG (The Capla 500 Project)

Blood (2023) 142 (Supplement 1): 2636.

https://doi.org/10.1182/blood-2023-179316

Published: 2023

Journal Articles

ADAMTS13 Conformation and Immunoprofiles in Japanese Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura

Kazuya Sakai, Masanori Matsumoto, Laure De Waele, Charlotte Dekimpe, Eriko Hamada, Masayuki Kubo, Claudia Tersteeg, Simon F De Meyer, Karen Vanhoorelbeke

Blood (2022) 140 (Supplement 1): 2790–2791.

https://doi.org/10.1182/blood-2022-159415

Published: 2022

Journal Articles

Redefining outcomes in immune TTP: an international working group consensus report

Adam Cuker, Spero R. Cataland, Paul Coppo, Javier de la Rubia, Kenneth D. Friedman, James N. George, Paul N. Knoebl, Johanna A. Kremer Hovinga, Bernhard Lӓmmle, Masanori Matsumoto, Katerina Pavenski, Flora Peyvandi, Kazuya Sakai, Ravi Sarode, Mari R. Thomas, Yoshiaki Tomiyama, Agnès Veyradier, John-Paul Westwood, Marie Scully

Blood (2021) 137 (14): 1855–1861.

https://doi.org/10.1182/blood.2020009150

Published: 2021

Includes: Supplemental data

Journal Articles

HLA loci predisposing to immune TTP in Japanese: potential role of the shared ADAMTS13 peptide bound to different HLA-DR

Blood (2020) 135 (26): 2413–2419.

https://doi.org/10.1182/blood.2020005395

Published: 2020

Includes: Supplemental data

Journal Articles

Next-Generation Sequencing of HLA Loci Identifies Predisposing and Protective Factors for Immune-Mediated Thrombotic Thrombocytopenic Purpura in a Japanese Population

Kazuya Sakai, MD, Masataka Kuwana, Hiroto Kojima, Hidenori Tanaka, Masayuki Kubo, Hideo Yagi, Masanori Matsumoto

Blood (2019) 134 (Supplement_1): 1085.

https://doi.org/10.1182/blood-2019-123927

Published: 2019

Journal Articles

Inhibitory Effect of a Novel DNA Aptamer with Artificial Nucleic Bases for Von Willebrand Factor A1 Domain on Platelet Thrombosis Formation

Kazuya Sakai, MD, Hideo Yagi, MD, Masaki Hayakawa, MD, Tatsuhiko Someya, PhD, Kaori Harada, PhD, Masanori Matsumoto, MD

Blood (2018) 132 (Supplement 1): 2522.

https://doi.org/10.1182/blood-2018-99-113948

Published: 2018

Journal Articles

Ischemia-Reperfusion Injury with Pringle's Maneuver Induces Increasing of Unusually Large Von Willebrand Factor Multimers after Hepatectomy

Takahiro Yoshikawa, MD, Takeo Nomi, MDPhD, Kazuya Sakai, MD, Masaki Hayakawa, MD, Daisuke Hokuto, MDPhD, Satoshi Yasuda, MDPhD, Masayuki Sho, MDPhD, Masanori Matsumoto, MD

Blood (2017) 130 (Supplement 1): 3608.

https://doi.org/10.1182/blood.V130.Suppl_1.3608.3608

Published: 2017

Journal Articles

Quantitative ELISA Using N10 Antibody, Targeting on VWF-Y1605 Residue, Indicates That N-Linked Blood Group Type A Carbohydrate on VWF Molecule Functions Against ADAMTS13 Cleavage

Masaki Hayakawa, MD, Seiji Kato, PhD, Taei Matsui, PhD, Kazuya Sakai, MD, Yumi Yoshii, MD, Hideo Yagi, MD.PhD, Yoshihiro Fujimura, MD, PhD, Masanori Matsumoto, MD.PhD

Blood (2016) 128 (22): 3773.

https://doi.org/10.1182/blood.V128.22.3773.3773

Published: 2016

Journal Articles

Clinical Significance of Risk Stratification Based on Disease Risk Index and Hematopoietic Cell Transplantation-Comorbidity Index

Takayuki Sato, MD PhD, Shinichi Ochi, MD, Takashi Nagayama, MD, Shogo Nabe, MD, Kazuya Sakai, MD, Hiroyuki Muranushi, MD, Yusuke Okamoto, MD, Hiroyuki Sugiura, MD, Kazuya Okada, MD, Aki Sato, MD PhD, Takeshi Maeda, MD, Tatsuhito Onishi, MD, Yasunori Ueda, MD PhD

Blood (2014) 124 (21): 2539.

https://doi.org/10.1182/blood.V124.21.2539.2539

Published: 2014

Journal Articles

Absolute Lymphocyte Count As an Independent Prognostic Factor of IPI and NCCN-IPI in DLBCL Patients

Kazuya Okada, MD, Shinichi Ochi, MD, Takashi Nagayama, MD, Shogo Nabe, MD, Kazuya Sakai, MD, Hiroyuki Muranushi, MD, Yusuke Okamoto, MD, Hiroyuki Sugiura, MD, Aki Sato, MD PhD, Takayuki Sato, MD PhD, Takeshi Maeda, MD, Tatsuhito Onishi, MD, Yasunori Ueda, MD PhD

Blood (2014) 124 (21): 1636.

https://doi.org/10.1182/blood.V124.21.1636.1636

Published: 2014

Journal Articles

SUV Max Reduction Criteria of Interim Positron Emission Tomography Improves Prognostic Value in Diffuse Large B-Cell Lymphoma: A Single-Center Retrospective Review

Yusuke Okamoto, MD, Shinichi Ochi, MD, Takashi Nagayama, MD, Shogo Nabe, MD, Kazuya Sakai, MD, Hiroyuki Muranushi, MD, Hiroyuki Sugiura, MD, Kazuya Okada, MD, Aki Sato, MD PhD, Takayuki Sato, MD PhD, Takeshi Maeda, MD, Tatsuhito Onishi, MD, Yasunori Ueda, MD PhD

Blood (2014) 124 (21): 1654.

https://doi.org/10.1182/blood.V124.21.1654.1654

Published: 2014

Journal Articles

Pre-Treatment WT1 mRNA Expression Level In Peripheral Blood Predicts Response and Overall Survival Of Myelodysplastic Syndrome Patients In The Azacitidine Era

Tomoyasu Jo, MD, Kazuya Sakai, MD, Hiroyuki Muranushi, MD, Yusuke Okamoto, MD, Taku Tsukamoto, MD, Hiroyuki Sugiura, MD, Hiroyuki Matsui, MD, Tomoaki Ueda, MD, Kazuya Okada, MD, Takeshi Maeda, MD, Tatsuhito Onishi, MD, Akane Kunitomi, MD, PhD, Yasunori Ueda, MD, PhD

Blood (2013) 122 (21): 1528.

https://doi.org/10.1182/blood.V122.21.1528.1528

Published: 2013

Journal Articles

The Curative Potential Of Fludarabine125, Melphalan100, and Busulfan4 As a Conditioning Regimen For Myeloid Malignancies Of Elderly Patients

Tomoaki Ueda, MD, Aki Sato, M.D., Kazuya Sakai, MD, Hiroyuki Muranushi, MD, Yusuke Okamoto, MD, Taku Tsukamoto, MD, Hiroyuki Sugiura, MD, Hiroyuki Matsui, MD, Tomoyasu Jo, MD, Kazuya Okada, MD, Takeshi Maeda, MD, Tatsuhito Onishi, MD, Akane Kunitomi, MD, PhD, Yasunori Ueda, MD, PhD

Blood (2013) 122 (21): 4551.

https://doi.org/10.1182/blood.V122.21.4551.4551

Published: 2013

NARROW

HLA Class I Allele-Deficient Clones Regenerate in Immune Aplastic Anemia without Anti-Thymocyte Globulin

Immediate Therapeutic Intervention for Acute Mortality in Immune-Mediated Thrombotic Thrombocytopenic Purpura with Positive Chest Findings at Initial Presentation

Persistent ADAMTS13 Inhibitor May Lead to Delayed ADAMTS13 Recovery in Japanese Patients with Caplacizumab-Treated Immune-Mediated Thrombotic Thrombocytopenic Purpura

Value of Prophylactic Plasma Treatment and Incidence of Acute Episodes in Patients Enrolled in the International Hereditary Thrombotic Thrombocytopenic Purpura Registry

Insight into the Natural History of Hereditary Thrombotic Thrombocytopenic Purpura: Short- and Long-Term Outcomes in a Longitudinally Followed Large Patient Cohort of the International Hereditary TTP Registry

Caplacizumab Frontline Added to Therapeutic Plasma Exchange and Immunosuppression Prevents Unfavorable Outcomes in Immune-Mediated TTP: An International Real-World Study of the TTP-IWG (The Capla 500 Project)

ADAMTS13 Conformation and Immunoprofiles in Japanese Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura

Redefining outcomes in immune TTP: an international working group consensus report

HLA loci predisposing to immune TTP in Japanese: potential role of the shared ADAMTS13 peptide bound to different HLA-DR

Next-Generation Sequencing of HLA Loci Identifies Predisposing and Protective Factors for Immune-Mediated Thrombotic Thrombocytopenic Purpura in a Japanese Population

Inhibitory Effect of a Novel DNA Aptamer with Artificial Nucleic Bases for Von Willebrand Factor A1 Domain on Platelet Thrombosis Formation

Ischemia-Reperfusion Injury with Pringle's Maneuver Induces Increasing of Unusually Large Von Willebrand Factor Multimers after Hepatectomy

Quantitative ELISA Using N10 Antibody, Targeting on VWF-Y1605 Residue, Indicates That N-Linked Blood Group Type A Carbohydrate on VWF Molecule Functions Against ADAMTS13 Cleavage

Clinical Significance of Risk Stratification Based on Disease Risk Index and Hematopoietic Cell Transplantation-Comorbidity Index

Absolute Lymphocyte Count As an Independent Prognostic Factor of IPI and NCCN-IPI in DLBCL Patients

SUV Max Reduction Criteria of Interim Positron Emission Tomography Improves Prognostic Value in Diffuse Large B-Cell Lymphoma: A Single-Center Retrospective Review

Pre-Treatment WT1 mRNA Expression Level In Peripheral Blood Predicts Response and Overall Survival Of Myelodysplastic Syndrome Patients In The Azacitidine Era

The Curative Potential Of Fludarabine125, Melphalan100, and Busulfan4 As a Conditioning Regimen For Myeloid Malignancies Of Elderly Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only